合計 50 件の最近のインサイダー取引記録が記録されています Sensei Biotherapeutics, Inc. (SNSE), 内訳は 30 件の買い および 14 件の売り. インサイダー買い総額は $34.69M インサイダー売り総額は $4.14M.
最近活動のある主要インサイダーには Parikh Anand Kiran, Donenberg Phillip B., Cambrian Biopharma Inc. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — SNSE
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-02-19 |
Parikh Anand Kiran |
Chief Operating Officer |
RSU 付与（制限付株式） |
1,239,305 |
$27.22 |
$33.73M |
1,239,305 |
| 2026-02-17 |
Parikh Anand Kiran |
Officer |
不明 |
- |
- |
- |
- |
| 2026-02-17 |
Parikh Anand Kiran |
Chief Operating Officer |
RSU 付与（制限付株式） |
56,673 |
$1.16 |
$65.74K |
56,673 |
| 2026-02-13 |
Donenberg Phillip B. |
Officer |
不明 |
- |
- |
- |
- |
| 2026-02-13 |
Donenberg Phillip B. |
Director |
RSU 付与（制限付株式） |
1,900 |
$9.09 |
$17.27K |
1,900 |
| 2025-12-09 |
Cambrian Biopharma Inc |
10 Percent Owner |
オプション行使（売却） |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-09 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
オプション行使（売却） |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-08 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
情報に基づく売り |
3,105 |
$8.59 |
$26.67K |
158,254 |
| 2025-12-05 |
Cambrian Biopharma Inc |
10 Percent Owner |
情報に基づく売り |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-05 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
情報に基づく売り |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-04 |
Cambrian Biopharma Inc |
10 Percent Owner |
情報に基づく売り |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-12-04 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
情報に基づく売り |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-11-14 |
Gerry Christopher |
President & Peo |
不明 |
5,881 |
$15.70 |
$92.34K |
- |
| 2025-05-21 |
Ricks Thomas G |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Ringo William R |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Cambrian Biopharma Inc |
10 Percent Owner |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Holmen Bob |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Peyer James |
10 Percent Owner |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Humer Kristian |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-02-19 |
Celebi John |
President and CEO |
RSU 源泉徴収 |
5,558 |
$0.48 |
$2.65K |
105,862 |
| 2025-02-19 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU 源泉徴収 |
2,276 |
$0.48 |
$1.08K |
59,794 |
| 2025-02-14 |
Celebi John |
President and CEO |
RSU 付与（制限付株式） |
360,000 |
$0.48 |
$171.36K |
360,000 |
| 2025-02-14 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU 付与（制限付株式） |
110,000 |
$0.48 |
$52.36K |
110,000 |
| 2025-02-14 |
Krebs Stephanie |
Chief Business Officer |
RSU 付与（制限付株式） |
120,000 |
$0.48 |
$57.12K |
120,000 |
| 2025-02-14 |
Craver Josiah |
Principal Financial Officer |
RSU 付与（制限付株式） |
50,000 |
$0.48 |
$23.8K |
50,000 |
| 2024-12-20 |
Celebi John |
President and CEO |
RSU 付与（制限付株式） |
355,000 |
$0.45 |
$159.71K |
355,000 |
| 2024-12-20 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU 付与（制限付株式） |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-12-20 |
Krebs Stephanie |
Chief Business Officer |
RSU 付与（制限付株式） |
120,000 |
$0.45 |
$53.99K |
120,000 |
| 2024-12-20 |
Craver Josiah |
Principal Financial Officer |
RSU 付与（制限付株式） |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-09-17 |
Craver Josiah |
Principal Financial Officer |
不明 |
80,000 |
$0.66 |
$52.8K |
- |
| 2024-06-11 |
Ricks Thomas G |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Ringo William R |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Cambrian Biopharma Inc |
10 Percent Owner |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Holmen Bob |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Vojta Deneen |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Peyer James |
10 Percent Owner |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
English Jessie |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Humer Kristian |
Director |
RSU 付与（制限付株式） |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-05-10 |
Gaiero David G |
Officer |
不明 |
- |
- |
- |
- |
| 2024-02-15 |
Celebi John |
President and CEO |
RSU 源泉徴収 |
5,891 |
$0.79 |
$4.65K |
105,420 |
| 2024-02-15 |
Colgan Erin |
Chief Financial Officer |
RSU 源泉徴収 |
3,627 |
$0.79 |
$2.87K |
67,462 |
| 2024-02-15 |
Van Der Horst Edward |
Chief Scientific Officer |
RSU 源泉徴収 |
2,843 |
$0.79 |
$2.25K |
56,070 |
| 2023-11-01 |
Krebs Stephanie |
Officer |
不明 |
- |
- |
- |
- |
| 2023-11-01 |
Krebs Stephanie |
Chief Business Officer |
RSU 付与（制限付株式） |
125,000 |
$0.82 |
$102.5K |
125,000 |
| 2023-09-11 |
Celebi John |
President and CEO |
情報に基づく買い |
500 |
$0.85 |
$425.00 |
111,311 |
| 2023-07-31 |
Cambrian Biopharma Inc |
10 Percent Owner |
株式返還 |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-31 |
Peyer James |
10 Percent Owner |
株式返還 |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-10 |
Ricks Thomas G |
Director |
RSU 付与（制限付株式） |
4,466 |
- |
- |
8,932 |
| 2023-07-10 |
Ringo William R |
Director |
RSU 付与（制限付株式） |
14,550 |
$1.22 |
$17.75K |
14,550 |
| 2023-07-10 |
Broder Samuel |
Director |
RSU 付与（制限付株式） |
4,466 |
- |
- |
8,932 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
